Roche Holding AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas Schinecker
- Full Time Employees
- 103,249
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Grenzacherstrasse 124 Basel Switzerland 4058
- IPO Date
- Feb 13, 2009
- Website
- roche.com
- Similar Companies
- Business
- Roche Holding AG develops, manufactures and markets pharmaceuticals and in vitro diagnostics worldwide. The company operates through its Pharmaceuticals and Diagnostics divisions; the Pharmaceuticals division offers prescription medicines addressing oncology, immunology, infectious diseases, ophthalmology, neuroscience, cardiovascular, renal and metabolic diseases, haemophilia, inflammatory and respiratory conditions; key products include monoclonal antibodies, antibody-drug conjugates and targeted therapies such as Tecentriq, Perjeta, Avastin, Hemlibra and Actemra; the Diagnostics division provides professional diagnostics systems and reagents for clinical chemistry, immunoassays, molecular diagnostics, tissue diagnostics and diabetes care including Accu-Chek glucose monitoring; additional offerings encompass point-of-care tests such as the recently FDA-cleared Bordetella infection diagnostic and sequencing technologies like those achieving Guinness World Record advances in 2025. Roche Holding AG maintains a global presence with operations in more than 130 countries, substantial manufacturing and R&D facilities in the United States including Genentech as a wholly owned subsidiary and a majority stake in Chugai Pharmaceutical in Japan. Founded in 1896 and headquartered in Basel, Switzerland, the company pursues recent strategic expansions including a USD 50 billion investment over five years announced in 2025 for new US R&D centres in Massachusetts focused on AI and cardiovascular-metabolic research, expanded manufacturing in Indiana for continuous glucose monitoring and weight loss medicines, gene therapy facilities in Pennsylvania and upgrades across multiple states creating over 12,000 jobs; it entered a definitive merger agreement in September 2025 to acquire 89bio for up to USD 3.5 billion to bolster its CVRM portfolio with pegozafermin for moderate to severe MASH; other moves encompass the 2024 acquisition of Carmot Therapeutics for USD 2.7 billion, 2023 purchase of Televant Holdings for USD 7.1 billion, partnerships like the antibody-drug conjugate deal with Innovent Biologics and licensing of CDK inhibitors from Regor Pharmaceuticals.
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease
Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
U.S.-Iran deal will stick despite being a ‘bad, bad deal', says David Roche
FDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCL
FDA approves first generic version of Roche's flu drug
JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study
Roche's Tecentriq Plus Chemo Gets FDA Priority Tag for Colon Cancer
Nurix Therapeutics Deal With Roche Is Worth Betting On
Roche Vs. Pfizer: Obesity Week Presentations Deep Dive - What Investors Must Know
Roche sticks to German investment after Eli Lilly cuts
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do
Olema: The Market Overreacted To Roche's SERD Failure
Isomorphic Labs' $2.1 Billion Fundraise Is The Biggest Bet Yet On AI Drug Discovery